ClinicalTrials.gg
CompletedNCT03423771Updated Apr 18, 2018

Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers

A Phase 1/2 interventional study of NPF-08 in Healthy Volunteers, sponsored by Nihon Pharmaceutical Co., Ltd. Completed at 1 site in Japan. Open to male participants aged 20 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-18.

Sponsored by Nihon Pharmaceutical Co., Ltd · Phase 1/2, Interventional, and Diagnostic

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2017, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
20 Years to 64 Years
Sex
Male
01

Study summary

Japanese male healthy volunteers will receive NPF-08. The efficacy of NPF-08 will be assessed by intestinal cleaning degree. The safety of NPF-08 will be evaluated based on adverse events and adverse drug reactions observed from the date of administration to 7 days after administration.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Nihon Pharmaceutical Co., Ltd is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese healthy male volunteers (20 to 64 years old)
  2. (Body Mass Index)should be within a range of 17.6 and 26.4.
  3. Subjects who agreed not to smoke or drink during hospital stay.
  4. Subjects who do not excessively consume alcohol and those who do not excessively smoke
  5. Subjects who are not judged as abnormal during the screening period in the physical examinations including 12-lead , clinical symptoms, clinical examination, immunological examination ( examination, examination, AIDS examination, syphilis examination).
  6. Subjects who are not judged as abnormal during the before administration in blood electrolyte.
  7. Subjects who have no clinical abnormalities and are judged to be eligible to the study by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who had previous significant gastrointestinal surgeries.
  2. Subjects with a history of 12-lead abnormality.
  3. Subjects who have constipation(less than 2 bowel movement per week)
  4. Subjects who have addictive of diarrhea
  5. Subjects who have history of shock or to sulfates (sodium sulfate, potassium sulfate, magnesium sulfate, etc.).
  6. Subjects who have history of drug allergy.
  7. Subjects who donated 200 mL or 400 mL of whole blood 4 weeks or 12 weeks respectively prior to the administration of drug, or who donated blood component last 2 weeks.
  8. Subjects who have participated in an investigational study within 4 months before signing the consent.
  9. Subjects who is participating in the other investigational study
  10. Subjects who received NPF-08 in the past
  11. Subjects who are judged by the investigator as not adequate to participate the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    NPF-08 Low dose (1-day treatment)

    Drug: NPF-08

  • Experimental
    NPF-08 Medium dose (2-day split dose)

    Drug: NPF-08

  • Experimental
    NPF-08 High dose (2-day split dose)

    Drug: NPF-08

  • Experimental
    NPF-08 Medium dose (1-day treatment)

    Drug: NPF-08

  • Experimental
    NPF-08 High dose (1-day treatment)

    Drug: NPF-08

  • Experimental
    NPF-08 Low~High dose (1-day treatment)

    Drug: NPF-08

  • Experimental
    NPF-08 Medium~High dose (2-day split dose)

    Drug: NPF-08

Interventions

  • DrugNPF-08

    Drug: NPF-08 Arms: NPF-08 oral sulfate solution

06

What researchers measure

Primary outcomes

  1. Effective rate of overall intestinal cleaning effect (after washing of the observed region) by the Endoscopic Image Evaluation Committee (EIEC)

    Time frame: 1day

Secondary outcomes

  1. Effective rate of overall intestinal cleaning effect (before washing of observed site) by EIEC

    Time frame: 1day

  2. Cleaning effect by intestinal site (before/after washing of observed site)

    Time frame: 1day

  3. Degree of bubbles by intestinal site

    Time frame: 1day

  4. Time for completion of the bowel cleaning

    Time frame: 1day or 2day

  5. Total dose of the investigational drug

    Time frame: 1day

  6. Acceptability by subjects

    Time frame: up to 6hr

  7. Coincidence rate of intestinal cleansing degree (before/after washing site of observation) between by EIEC members

    Time frame: 1day

  8. Coincidence rate between the intestinal cleansing degrees evaluated by EIEC and the endoscope operators (before/after the observed site)

    Time frame: 1day

07

Study locations

1 site
  • Osaka
    Osaka, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Feb 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 6, 2018
StartActual
Oct 6, 2017
Primary completionActual
Feb 23, 2018
CompletionActual
Feb 28, 2018
Last update
Apr 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03423771
Lead sponsor
Nihon Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Oct 6, 2017
Primary completion
Feb 23, 2018
Completion
Feb 28, 2018
Last update
Apr 18, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion